Suggested Reading
Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1351–1354, 2009.
Armstrong AJ, Eisenberger MA, Halabi S, et al: Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 61:549–559, 2012.
Armstrong AJ, Garrett-Mayer E, de Wit R, et al: Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203–211, 2010.
Armstrong AJ, Garrett-Mayer ES, Yang YC, et al: A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 13:6396–6403, 2007.
Armstrong AJ, Tannock IF, de Wit R, et al: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517–525, 2010.
Attard G, Reid AH, A'Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3732–3748, 2009.
Bañez LL, Hamilton RJ, Partin AW, et al: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298:2275–2280, 2007.
Barry MJ: Screening for prostate cancer—The controversy that refuses to die. N Engl J Med 360:1351–1354, 2009.
Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578, 2005.
Briganti A, Karnes RJ, Da Pozzo LF, et al: Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis. Eur Eurol 59:832–840, 2011.
Calais da Silva FE, Bono AV, Whelan P, et al: Intermittent androgen deprivation for locally advance and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 55:1269–1277, 2009.
D'Amico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289–295, 2008.
D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425, 2007.
de Bono JS, Logothetis C, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005, 2011.
de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147–1154, 2010.
de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309, 2008.
Droz JP, Balducci L, Bolla M, et al: Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106:462–469, 2010.
Freedland SJ, Humphreys EB, Mangold LA, et al: Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765–1771, 2007.
Freedland SJ, Mavropoulos J, Wang A, et al: Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68:11–19, 2008.
Giovannucci E, Liu Y, Platz EA, et al: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121:1571–1578, 2007.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 60:277–300, 2010.
Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med: 363:411–422, 2010.
Kawachi MH, Bahnson RR, Barry M, et al: NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Comp Canc Netw 8:240–262, 2010.
Keating NL, O'Malley AJ, Freedland SJ, et al: Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39–46, 2010.
Kirsh VA, Peters U, Mayne ST, et al: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 99:1200–1209, 2007.
Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131, 2010.
Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596–1605, 2007.
Lu-Yao GL, Albertsen PC, Moore DF, et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173–181, 2008.
Lu-Yao GL, Albertsen PC, Moore DF, et al: Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209, 2009.
Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479, 2006.
Mostaghel EA, Nelson PS: Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Enocrinol Metab 22:242–258, 2008.
Moul JW, Wu H, Sun L, et al: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 179(5s):S53–S59, 2008.
Murphy DG, Bjartell A, Ficarra V, et al: Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol 57:735–746, 2010.
Parker C, Nilsson S, Heinrich D, et al: Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 30(suppl): abstract LBA4512, 2012.
Pili R, Haggman M, Stadler WM, et al: Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29:4022–4028, 2011.
Ryan CJ, Smith MR, deBono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148, 2013.
Ryan CJ, Smith MR, Fong L, et al: Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488, 2010.
Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261, 2008.
Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197, 2012.
Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159, 2008.
Schröder FH, Hugosson J, Roobol MJ, et al: ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328, 2009.
Schröder FH, Roach M 3rd, Scardino P: Clinical decisions: Management of prostate cancer. N Engl J Med 359:2605–2609, 2008.
Stephenson AJ, Kattan MW, Eastham JA, et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300–4305, 2009.
Tang P, Sun L, Uhlman MA, et al: Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 183:946–950, 2010.
Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529–534, 2006.
Thompson I, Trasher JB, Aus G, et al: AUA Prostate Cancer Clinical Guideline Update Panel: Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131, 2007.
Tran C, Ouk S, Clegg NJ, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790, 2009.
Trock BJ, Han M, Freedland SJ, et al: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769, 2008.
Walsh PC, DeWeese TL, Eisenberger MA: Clinical practice: Localized prostate cancer. N Engl J Med 357:2696–2705, 2007.
Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2011.
Wong YN, Mitra N, Hudes G, et al: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296:2683–2693, 2006.
Zheng SL, Sun J, Wiklund F, et al: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358:910–919, 2008.
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has metastasized to the bone but no other organs.
